KRAS mutations are observed in up to 20% of all human cancers and drive tumorigenesis in the 3 most lethal cancers in the United States, including adenocarcinomas of the pancreas (PAAD: 80%–90%), colon (COAD: 40%–50%), and lung (LUAD: 30%–40%) (8). This evidence concerns the gene KRAS and pancreatic adenocarcinoma.